Marshall Wace North America’s Meridian Bioscience Inc VIVO Stock Holding History

Marshall Wace North America’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-211,248	Closed	-$3.95M	–	1869
2020 Q4	$3.95M	Buy	211,248 +90,632	+75%	+$1.69M	0.02%	593
2020 Q3	$2.05M	Buy	+120,616	New	+$2.34M	0.01%	581
2020 Q1	–	Sell	-3,588	Closed	-$35K	–	1704
2019 Q4	$35K	Sell	3,588 -34,152	-90%	-$321K	﹤0.01%	1181
2019 Q3	$358K	Buy	+37,740	New	+$398K	﹤0.01%	862
2019 Q1	–	Sell	-6,908	Closed	-$120K	–	2000
2018 Q4	$120K	Buy	+6,908	New	+$118K	﹤0.01%	1048

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Marshall Wace North America's VIVO Position: Q1 2021 in Review

Marshall Wace North America sold out of Meridian Bioscience Inc (VIVO) in Q1 2021, closing a stake of 211,248 shares — an estimated $3.95M sold.

Marshall Wace North America first reported a position in VIVO in Q4 2018 and held it in 5 quarters. The position peaked at $3.95M in Q4 2020. 215 funds tracked by Wall St. Rank hold VIVO as of Q1 2021.

Marshall Wace North America reported no remaining Meridian Bioscience Inc position as of Q1 2021 after selling out during the quarter.
Marshall Wace North America sold 211,248 Meridian Bioscience Inc shares in Q1 2021, an estimated $3.95M.
Marshall Wace North America first reported a position in Meridian Bioscience Inc in Q4 2018 and held it in 5 quarters.
Marshall Wace North America's Meridian Bioscience Inc position peaked at $3.95M in Q4 2020.
215 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.